Neurogene Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGNE research report →
Range $65 – $81
Price Chart
About the company
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease).
- CEO
- Rachel L. McMinn
- IPO
- 2014
- Employees
- 131
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on NGNE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $350.02M
- P/E
- -3.98
- Fwd P/E
- 5.07
- PEG
- 0.18
- P/S
- 0.00
- P/B
- 1.73
- EV/EBITDA
- -2.40
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -44.36%
- ROIC
- -35.82%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-3,192,000-37.5%
- Op Income
- $-103,208,000
- Net Income
- $-90,351,000-20.2%
- EPS
- $-4.24+0.9%
- OCF Growth
- -9.3%
- FCF Growth
- -9.7%
- 52W High
- $43.66
- 52W Low
- $15.93
- 50D MA
- $27.05
- 200D MA
- $28.28
- Beta
- 2.09
- RSI (14)
- 35
- Avg Volume
- 310.41K
No earnings-call transcripts are available for NGNE yet.
- Free Float
- 79.3%
- Shares Outstanding
- 15.80M
- Float Shares
- 12.54M
of shares held by institutions
117 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jennison Associates LLC | 2.23M | ▲ 1.71M |
| Samsara Biocapital, LLC | 1.87M | ▲ 150.00K |
| Casdin Capital, LLC | 1.59M | ▲ 40.00K |
| Redmile Group, LLC | 1.56M | ▲ 150.00K |
| Rtw Investments, LP | 1.51M | ▲ 150.00K |
| Blackrock, Inc. | 1.47M | ▲ 413.95K |
| Ecor1 Capital, LLC | 1.27M | 0 |
| Baker Bros. Advisors LP | 991.69K | 0 |
| Trails Edge Capital Partners, LP | 964.88K | ▲ 250.00K |
| T. Rowe Price Investment Management, Inc. | 850.12K | ▲ 850.12K |
| Mpm Bioimpact LLC | 771.84K | ▲ 771.84K |
| Vanguard Capital Management LLC | 711.29K | ▲ 174.76K |
Held by 151 ETFs
Biggest fund positions in NGNE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 22, 26 | McMinn Rachel | other | 756 |
| Sep 22, 26 | McMinn Rachel | other | 756 |
| Jul 6, 26 | Cvijic Christine Mikail | sell | 600 |
| Jul 7, 26 | Cvijic Christine Mikail | sell | 4,200 |
| Jul 1, 26 | Cvijic Christine Mikail | sell | 739 |
| Jul 2, 26 | Cvijic Christine Mikail | sell | 2,531 |
| Jul 2, 26 | Cvijic Christine Mikail | sell | 1,530 |
| Jan 16, 24 | Woods Keith | other | 15,400 |
| Jun 14, 24 | Woods Keith | other | 7,700 |
| Jun 12, 25 | Woods Keith | other | 12,050 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NGNE coverage
Recent articles, reports, and earnings notes.
No research on NGNE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGNE report →Does Neurogene (NGNE) Have the Potential to Rally 203.28% as Wall Street Analysts Expect?
zacks.com · Nov 11
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
gurufocus.com · Nov 9
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
businesswire.com · Nov 9
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 5
Neurogene to Participate in Upcoming Investor Conferences
businesswire.com · Nov 3
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
gurufocus.com · Oct 27
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
businesswire.com · Oct 27
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey
defenseworld.net · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.